My Crossword Maker Logo
Powered by BrightSprout
Save Status:
or to save your progress. The page will not refresh.
Controls:
SPACEBAR SWITCHES TYPING DIRECTION
Answer Key:
Edit a Copy:
Make Your Own:
Crucigrama Sopa de Letras Hoja de Trabajo
Calificar este Puzzle:
Log in or sign up to rate this puzzle.

The Cynical Scribe's Guide to the Top Twenty Oncology Labs of North America - USCAP 2025 Edition

Looking for granular and up-to-date intelligence on cancer testing markets in the US, Europe, and Japan? Contact [email protected] for a Zoom tour of our research.
Horizontales
We're #16 and a recovering Covid-addict, but we also run the two busiest anatomic pathology labs in North America.
We're #20. We're newly hatched, and we can tell you what you should be worried about.
We're #8. We sequence near the Salt Lake. We wrote the book on training your MAC to pay premium prices.
We're #15. KonicaMinolta bought us for $1b in 2017, then sold us to Tempus for $600m last year.
We're #19, the Seattle brotherly MRD lab.
We're #10. This year we made $25m on revenue of $446m. We've got the first profitable proprietary NGS panel.
We're #13 - the northerly academic reference lab.
We're #18, the easterly academic reference lab.
We were #12 last year but we'll probably be #8 this year. $705m cash burn on $693m revenue - what, me worry?
G'Day Mate, we're #6. Please be patient...we're still stalking the NGS business...not quite ready to pounce.
Verticales
We're #17, the westerly academic reference lab.
We're #4. We're the big footprint, big menu lab with the C-suite in New Jersey. Cancer testing brings us just 9-10% of sales.
We're #11. Our CGP panel is the most C (by far).
We're #5. The good news in 2024 was 31% revenue growth. The bad news: we lost $436m on $739m revenue.
We're #7 in the US, and we've also got the biggest overseas oncology footprint of any American lab.
We're #9. We're the Boston CGP team. It used to be so easy (wistful sigh)...
We're #3. We're the big footprint, big menu lab with the C-suite in Carolina. Cancer testing brings us just 8-9% of sales.
We're #14 - that low profile, privately held regional lab with a C-suite in Middle Tennessee.
We're #2. Last year we became the world's #1 sequencing lab (by revenue). We lost $190m during 2024, but in '23 we torched $435m.
We're #1. Last year we turned 4.4m packages of stool into as many $475 invoices. Still we burned through $1b.